As supply chains become more fragmented and biologics programs grow more complex, the ability to seamlessly connect drug substance and drug product manufacturing has become a genuine competitive advantage.
In this 30 minute webinar, Lonza experts draw on real cross-site DS/DP case studies to show how an integrated CDMO model can reduce CMC risk, simplify regulatory submissions, and keep commercial timelines on track.
Featured case studies:
- A mid-size biotech navigated a
formulation switch from liquid to lyophilized mid-program without disrupting clinical timelines.
- Another team transitioned from stainless steel to single-use systems, drawing on shared DS/DP compatibility data to avoid delays.
- A single multi-site program manager reduced the coordination overhead that comes with managing separate CDMO partners.
